Jinghui Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jinghui Wang has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Changlong Li
Beijing Key Laboratory of Cancer Invasion and Metastasis Research, Department of Medical Genetics and Developmental Biology, School of Basic Medical Science, Capital Medical University, Beijing 100069, China
1 shared publication Daping Yu
Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China
1 shared publication- Hongxia Li
Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China
1 shared publication - Jia-Nan Gong
Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
1 shared publication - Jianyi Lv
School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China
1 shared publication - Jing Lu
School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China
1 shared publication
Latest Publications
- Open Access
- 1 September 2025
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 14 (9) , 3396-3409
Efficacy and safety of neoadjuvant chemotherapy with or without PD-L1/PD-1 inhibitors in surgically limited-stage small-cell lung cancer
Background: Small-cell lung cancer (SCLC) is a highly aggressive form of lung cancer. The emergence of chemoimmunotherapy has changed the mode of SCLC treatment. However, in limited-stage SCLC (LS-SCLC), the effectiveness and safety of chemoimmunotherapy in the neoadjuvant setting for LS-SCLC are not well-established. To address this gap, we conducted a study to evaluate neoadjuvant chemoimmunotherapy in LS-SCLC. Methods: A retrospective study was conducted on patients from Beijing Chest Hospital, Capital Medical University, who underwent etoposide-based chemotherapy with programmed death-ligand 1/programmed death 1 (PD-L1/PD-1) inhibitors (neoCIT group) or without (neoCT group) prior to surgery for LS-SCLC between April 2019 and March 2023. The primary endpoints were to evaluate the major pathological response (MPR) and the pathological complete response (pCR). Secondary endpoints comprised event-free survival (EFS), overall survival (OS), and safety. Results: A total of 31 patients with stage IIB-IIIB LS-SCLC were included, comprising 16 cases in the neoCIT group and 15 patients in the neoCT group. A pCR was observed in eight cases [50.0%; 95% confidence interval (CI): 28.0 to 72.0] within the neoCIT group, compared to one patient (6.7%; 95% CI: 0.3 to 29.8) in the neoCT group (odds ratio, 14.00; 95% CI: 1.71 to 164.20; P=0.02). An MPR was observed in 14 cases (87.5%; 95% CI: 64.0 to 97.8) within the neoCIT group, while three patients (20.0%; 95% CI: 7.0 to 45.2) were noted in the neoCT group, yielding an odds ratio of 28.00 (95% CI: 4.23 to 150.50; PConclusions: Our study underscores the potential of neoadjuvant chemoimmunotherapy in resectable SCLC patients. The significant improvements in pCR, MPR, EFS, and OS compared to neoadjuvant chemotherapy alone offer a promising outlook for the future management of LS-SCLC.
- 1 September 2025
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 14 (9) , 3396-3409
Open AccessEfficacy and safety of neoadjuvant chemotherapy with or without PD-L1/PD-1 inhibitors in surgically limited-stage small-cell lung cancer
Background: Small-cell lung cancer (SCLC) is a highly aggressive form of lung cancer. The emergence of chemoimmunotherapy has changed the mode of SCLC treatment. However, in limited-stage SCLC (LS-SCLC), the effectiveness and safety of chemoimmunotherapy in the neoadjuvant setting for LS-SCLC are not well-established. To address this gap, we conducted a study to evaluate neoadjuvant chemoimmunotherapy in LS-SCLC. Methods: A retrospective study was conducted on patients from Beijing Chest Hospital, Capital Medical University, who underwent etoposide-based chemotherapy with programmed death-ligand 1/programmed death 1 (PD-L1/PD-1) inhibitors (neoCIT group) or without (neoCT group) prior to surgery for LS-SCLC between April 2019 and March 2023. The primary endpoints were to evaluate the major pathological response (MPR) and the pathological complete response (pCR). Secondary endpoints comprised event-free survival (EFS), overall survival (OS), and safety. Results: A total of 31 patients with stage IIB-IIIB LS-SCLC were included, comprising 16 cases in the neoCIT group and 15 patients in the neoCT group. A pCR was observed in eight cases [50.0%; 95% confidence interval (CI): 28.0 to 72.0] within the neoCIT group, compared to one patient (6.7%; 95% CI: 0.3 to 29.8) in the neoCT group (odds ratio, 14.00; 95% CI: 1.71 to 164.20; P=0.02). An MPR was observed in 14 cases (87.5%; 95% CI: 64.0 to 97.8) within the neoCIT group, while three patients (20.0%; 95% CI: 7.0 to 45.2) were noted in the neoCT group, yielding an odds ratio of 28.00 (95% CI: 4.23 to 150.50; PConclusions: Our study underscores the potential of neoadjuvant chemoimmunotherapy in resectable SCLC patients. The significant improvements in pCR, MPR, EFS, and OS compared to neoadjuvant chemotherapy alone offer a promising outlook for the future management of LS-SCLC.
- 7 September 2023
- Published by Wiley in The FASEB Journal
- Vol. 37 (10) , e23170
ELAVL4 promotes the tumorigenesis of small cell lung cancer by stabilizing LncRNA LYPLAL1‐DT and enhancing profilin 2 activation
Small cell lung cancer (SCLC) is one of the most malignant tumors that has an extremely poor prognosis. RNA‐binding protein (RBP) and long noncoding RNA (lncRNA) have been shown to be key regulators during tumorigenesis as well as lung tumor progression. However, the role of RBP ELAVL4 and lncRNA LYPLAL1‐DT in SCLC remains unclear. In this study, we verified that lncRNA LYPLAL1‐DT acts as an SCLC oncogenic lncRNA and was confirmed in vitro and in vivo. Mechanistically , LYPLAL1‐DT negatively regulates the expression of miR‐204‐5p, leading to the upregulation of PFN2, thus, promoting SCLC cell proliferation, migration, and invasion. ELAVL4 has been shown to enhance the stability of LYPLAL1‐DT and PFN2 mRNA. Our study reveals a regulatory pathway, where ELAVL4 stabilizes PFN2 and LYPLAL1‐DT with the latter further increasing PFN2 expression by blocking the action of miR‐204‐5p. Upregulated PFN2 ultimately promotes tumorigenesis and invasion in SCLC. These findings provide novel prognostic indicators as well as promising new therapeutic targets for SCLC.
- 7 September 2023
- Published by Wiley in The FASEB Journal
- Vol. 37 (10) , e23170
ELAVL4 promotes the tumorigenesis of small cell lung cancer by stabilizing LncRNA LYPLAL1‐DT and enhancing profilin 2 activation
Small cell lung cancer (SCLC) is one of the most malignant tumors that has an extremely poor prognosis. RNA‐binding protein (RBP) and long noncoding RNA (lncRNA) have been shown to be key regulators during tumorigenesis as well as lung tumor progression. However, the role of RBP ELAVL4 and lncRNA LYPLAL1‐DT in SCLC remains unclear. In this study, we verified that lncRNA LYPLAL1‐DT acts as an SCLC oncogenic lncRNA and was confirmed in vitro and in vivo. Mechanistically , LYPLAL1‐DT negatively regulates the expression of miR‐204‐5p, leading to the upregulation of PFN2, thus, promoting SCLC cell proliferation, migration, and invasion. ELAVL4 has been shown to enhance the stability of LYPLAL1‐DT and PFN2 mRNA. Our study reveals a regulatory pathway, where ELAVL4 stabilizes PFN2 and LYPLAL1‐DT with the latter further increasing PFN2 expression by blocking the action of miR‐204‐5p. Upregulated PFN2 ultimately promotes tumorigenesis and invasion in SCLC. These findings provide novel prognostic indicators as well as promising new therapeutic targets for SCLC.